Daiichi Sankyo Company, Limited

Equities

4568

JP3475350009

Market Closed - Japan Exchange Other stock markets 02:30:00 2026-06-05 am EDT			5-day change	1st Jan Change
2,490.00 ^JPY	+4.10%		-7.79%	-25.63%

Jun. 05	Worldwide Healthcare Trust outperforms benchmark; praises AstraZeneca	AN
May. 28	Daiichi Sankyo concludes pcpa letter of intent for Vanflyta®	RE

Transcript : Daiichi Sankyo Company, Limited, 2026 Earnings Call, May 11, 2026

Published on 05/11/2026 at 12:21 pm EDT - Modified on 05/11/2026 at 04:53 pm EDT

S&P Capital IQ

Presenter Speech
Ari Fujishiro (Executives)

[interpreted]

Thank you for waiting. We are going to start Daiichi Sankyo's FY 2025 Financial Results Announcement and FY

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Daiichi Sankyo Company, Limited

Jun. 05	Worldwide Healthcare Trust outperforms benchmark; praises AstraZeneca	AN
May. 28	Daiichi Sankyo concludes pcpa letter of intent for Vanflyta®	RE
May. 28	Daiichi Sankyo Presents New Clinical Research And Product Pipeline Updates Across Oncology Portfolio At ASCO	CI
May. 26	AstraZeneca says Datroway approved in US for 1L triple-negative BC	RE
May. 22	FTSE 100 Closes Week Upbeat; AstraZeneca Sees Oncology Approval Progress	MT
May. 22	AstraZeneca Breast Cancer Drug Recommended for Approval by EU Regulator	DJ
May. 22	AstraZeneca and Daiichi cancer drugs clear regulatory hurdles	AN
May. 22	AstraZeneca, Daiichi Sankyo Win US FDA Approval for Datroway to Treat Triple-Negative Breast Cancer	MT
May. 22	AstraZeneca, Daiichi Sankyo's Breast Cancer Drug Wins US FDA Approval	MT
May. 22	Daiichi Sankyo and Astrazeneca Announce Approval of Datroway as First Trop2 Directed Antibody Drug Conjugate for First-Line Treatment of Metastatic Triple Negative Breast Cancer in the U.S	CI
May. 22	AstraZeneca, Daiichi Sankyo's Enhertu Recommended for EU Approval for HER2-Positive Solid Tumors	MT
May. 22	AstraZeneca, Daiichi Sankyo Win EU Panel's Recommendation for Metastatic Solid Tumors Therapy	MT
May. 22	Daiichi Sankyo and Astrazeneca Announce Enhertu's Recommendation for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors	CI
May. 22	EMA's CHMP recommends extension to marketing authorisation for Wegovy	RE
May. 21	Astrazeneca Receives CHMP Recommendation for Enhertu Approval in the Eu for Previously Treated Her2-Positive Metastatic Solid Tumours	CI